148 related articles for article (PubMed ID: 33222957)
1. A pediatric case of anaplastic astrocytoma with a gliomatosis cerebri; the growth pattern and changes in serum VEGF-121 levels after bevacizumab treatment.
Ninomiya H; Ozeki M; Matsuzawa Y; Nozawa A; Yasue S; Kubota K; Endo S; Asano T; Taguchi K; Ohe N; Matsuo M; Iwama T; Ohnishi H
J Clin Neurosci; 2020 Nov; 81():431-433. PubMed ID: 33222957
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
[TBL] [Abstract][Full Text] [Related]
3. Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration.
Lodi R; Setola E; Tonon C; Ambrosetto P; Franceschi E; Crinò L; Barbiroli B; Cortelli P
Magn Reson Imaging; 2003 Nov; 21(9):1003-7. PubMed ID: 14684203
[TBL] [Abstract][Full Text] [Related]
4. VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
Martini M; de Pascalis I; D'Alessandris QG; Fiorentino V; Pierconti F; Marei HE; Ricci-Vitiani L; Pallini R; Larocca LM
BMC Cancer; 2018 May; 18(1):553. PubMed ID: 29747600
[TBL] [Abstract][Full Text] [Related]
5. Initial chemotherapy in gliomatosis cerebri.
Sanson M; Cartalat-Carel S; Taillibert S; Napolitano M; Djafari L; Cougnard J; Gervais H; Laigle F; Carpentier A; Mokhtari K; Taillandier L; Chinot O; Duffau H; Honnorat J; Hoang-Xuan K; Delattre JY;
Neurology; 2004 Jul; 63(2):270-5. PubMed ID: 15277619
[TBL] [Abstract][Full Text] [Related]
6. [Gliomatosis cerebri].
Sanson M; Napolitano M; Cartalat-Carel S; Taillibert S
Rev Neurol (Paris); 2005 Feb; 161(2):173-81. PubMed ID: 15798516
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Levin N; Gomori JM; Siegal T
Neurology; 2004 Jul; 63(2):354-6. PubMed ID: 15277636
[TBL] [Abstract][Full Text] [Related]
8. Comparative Histologic and Molecular Analysis of 2 Recurrent Lesions Showing Different Magnetic Resonance Imaging Responses After Bevacizumab Treatment: Report of a Case of Anaplastic Astrocytoma.
Otani Y; Ichikawa T; Uneda A; Kurozumi K; Ishida J; Date I
World Neurosurg; 2018 Aug; 116():464-471.e1. PubMed ID: 29772361
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.
Burger MC; Mildenberger IC; Wagner M; Mittelbronn M; Steinbach JP; Bähr O
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353668
[TBL] [Abstract][Full Text] [Related]
10. Gliomatosis cerebri: better definition, better treatment.
Chamberlain MC
Neurology; 2004 Jul; 63(2):204-5. PubMed ID: 15277608
[No Abstract] [Full Text] [Related]
11. Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases.
Kwon MJ; Kang SY; Cho H; Lee JI; Kim ST; Suh YL
Brain Pathol; 2020 Mar; 30(2):235-245. PubMed ID: 31435963
[TBL] [Abstract][Full Text] [Related]
12. Gliomatosis cerebri: molecular pathology and clinical course.
Herrlinger U; Felsberg J; Küker W; Bornemann A; Plasswilm L; Knobbe CB; Strik H; Wick W; Meyermann R; Dichgans J; Bamberg M; Reifenberger G; Weller M
Ann Neurol; 2002 Oct; 52(4):390-9. PubMed ID: 12325066
[TBL] [Abstract][Full Text] [Related]
13. An enduring debate on gliomatosis cerebri.
Akimoto J
Brain Tumor Pathol; 2023 Apr; 40(2):78-84. PubMed ID: 37022648
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1.
Falchetti ML; D'Alessandris QG; Pacioni S; Buccarelli M; Morgante L; Giannetti S; Lulli V; Martini M; Larocca LM; Vakana E; Stancato L; Ricci-Vitiani L; Pallini R
Int J Cancer; 2019 Mar; 144(6):1331-1344. PubMed ID: 30414187
[TBL] [Abstract][Full Text] [Related]
15. Alterations of cell cycle regulators in gliomatosis cerebri.
Mawrin C; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Mawrin A; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Mawrin A; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Mawrin A; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Deimling A; Stoltenburg-Didinge G; Bornemann A; Romeike B; Sellhaus B; Dietzmann K
J Neurooncol; 2005 Apr; 72(2):115-22. PubMed ID: 15925990
[TBL] [Abstract][Full Text] [Related]
16. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
Sathornsumetee S; Cao Y; Marcello JE; Herndon JE; McLendon RE; Desjardins A; Friedman HS; Dewhirst MW; Vredenburgh JJ; Rich JN
J Clin Oncol; 2008 Jan; 26(2):271-8. PubMed ID: 18182667
[TBL] [Abstract][Full Text] [Related]
17. Gliomatosis Cerebri Among Children and Adolescents: An Individual-Patient Data Meta-analysis of 182 Patients.
Georgakis MK; Tsivgoulis G; Pourtsidis A; Petridou ET
J Child Neurol; 2019 Jun; 34(7):394-401. PubMed ID: 30887873
[TBL] [Abstract][Full Text] [Related]
18. High expression of a novel splicing variant of VEGF, L-VEGF144 in glioblastoma multiforme is associated with a poorer prognosis in bevacizumab treatment.
Cheng WY; Shen CC; Chiao MT; Liang YJ; Mao TF; Liu BS; Chen JP
J Neurooncol; 2018 Oct; 140(1):37-47. PubMed ID: 29909500
[TBL] [Abstract][Full Text] [Related]
19. Gliomatosis cerebri: post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide.
Mawrin C; Aumann V; Kirches E; Schneider-Stock R; Scherlach C; Vogel S; Mittler U; Dietzmann K; Krause G; Weis S
J Neurooncol; 2001 Oct; 55(1):11-7. PubMed ID: 11804278
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological study of cellular proliferation and invasion in gliomatosis cerebri: important role of neural cell adhesion molecule L1 in tumour invasion.
Suzuki T; Izumoto S; Fujimoto Y; Maruno M; Ito Y; Yoshimine T
J Clin Pathol; 2005 Feb; 58(2):166-71. PubMed ID: 15677537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
